(Date:11/21/2008)...ALE, N.J., Nov. 21 Barr ...ed that its shareholders overwhelmingly approved t...uisition of Barr by Teva Pharmaceuticals Industrie...e demonstrated the overwhelming support of the tra...Downey, Barr,s Chairman and CEO. "We are pleased w...
(Date:11/21/2008)...430 B.C., a new and deadly diseaseits cause remain...y-state was teeming with citizens, soldiers and re...parta. As streets filled with corpses, social orde...ss returned twice and Athens lost a third of its p...ns marked the beginning of the end of the Golden A...
(Date:11/21/2008)...OCHELLE, N.Y., Nov. 21 A prestigio...are providers will gather in Williamsburg, VA on M...n practical, clinical information on cutting-edge ..., and innovative research advances that impact pat...n, and registration information is available at w...
(Date:11/21/2008)...EW YORK Tobacco use is more prevalent and smoki...ion Deficit Hyperactivity Disorder (A.D.H.D.) In ...ractivity symptoms, those who exhibited elevated h...tention, showed lower quit rates after 8 weeks tha...ithout the A.D.H.D. symptoms. The study, now avai...
Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2...Complication as its other name. Among the many com... would be the foot ulcer, as damage can be severe ...his dreaded foot ulcer, a boon in disguise would b...age electric current to the skin. //Such an electr...
...sease as so much of research are going on in ident... ongoing research, hyperhomocysteinemia (increased... be one of the risk factors.// Dr. O Mayer Jr and ...lsen, Czech Republic, found as a result of their s...
...ts as pets had developed a better immune system ag...to suppport the "hygiene"or "cleanliness" hypothes... bacteria or allergens keeps one branch of our imm...rom developing properly. As a result, the immune s...
...in shrinkage in social drinkers. Chronic heavy alc...Dr. Motoo Kubota and colleagues from Chiba Univers...al of Neurology, Neurosurgery & Psychiatry. Alcoho...physically and mentally, now turns out to potentia...
Other Medicine News:(Date:11/19/2008)...udy did not achieve statistical significance , .../ -- Pharmos Corporation (Nasdaq: PARS ) today a...of its topical NanoEmulsion (NE) drug delivery tec...ne. , , The multi-center, randomized, doubl...safety and efficacy of the Company,s 3% Diclofenac...
(Date:11/19/2008)...illion Payment from Roche- , , MONTVALE, N....aceuticals Corp. (Nasdaq: MEMY ) today announced...Phase 2 trial of R3487/MEM 3454, its lead alpha-7 ...t associated with schizophrenia (CIAS). The Compa...l, triggering a $5.0 million payment from its part...
(Date:11/18/2008)..., Nov. 18 Forty-two lea...a November national forum to consider cutting-edge...th and national economy from outbreaks of dangerou...ay. , , Among those innovations: , , ...n kitchen table that detects highly contagious and...
(Date:11/13/2008)...Suggests Nutritional Supplements Prior to Surgery,...ewswire/ -- Identifying,malnutrition before surger...touring will significantly decrease surgical compl...uality and boost patient energy levels,according ...constructive,Surgery(R), the official medical jour...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 1Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 1Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 2Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 3Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 5DuraHeart 28TM 29 LVAS Receives Conditional Approval for US Pivotal Trial 1452 1DuraHeart 28TM 29 LVAS Receives Conditional Approval for US Pivotal Trial 1452 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 1Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 4...at Leading Influenza Conference , HIGH WYCOMBE, UK...l data showing how a new flu vaccine has the poten...including pandemic and,annual, was presented today...of Influenza VI (Options) Conference, in Toronto,...published in the,European Journal of Immunology, s...
...es Identification, Characterization and Broad,Neur...harmacology,and Experimental Therapeutics , Neurod... a Novel,Drug Candidate for ALS That Targets Mitoc...rophos SA, a biopharmaceutical,company specializin...urological disorders, announced today that a publi...
Other Medicine Technology:New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4New Flu Vaccine from PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 5Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 2Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 3Trophos Publishes ALS Article in Journal of Pharmacology and,Experimental Therapeutics 4For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the in vitro quantitative determination of glucose in human serum or plasma.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products: